Shortly after President-elect Donald J. Trump nominated Robert F. Kennedy Jr. to lead the Department of Health and Human Services (HHS), the biotech market — specifically those involving vaccines — ...

We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In this article, we are going to ...

Shares of Novavax Inc. NVAX slid 3.46% to $9.22 Friday, on what proved to be an all-around rough trading session for the ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $9.55 which represents a slight increase of $0.72 or 8.15% from the prior close of $8.83. The stock opened at $8.82 and touched a low of ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna ...

Bullish option flow detected in Novavax (NVAX) with 15,743 calls trading, 1.7x expected, and implied vol increasing over 2 points to 73.97%.

With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the ...